A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Phase 3

Completed

• Conditions: Crohn Disease
• Interventions: Biological: Cimzia

• Registration Number: NCT00552344
• Lead Sponsor: UCB BIOSCIENCES GmbH

Brief Summary

The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 \[NCT00552058\].

Detailed Description

This study consisted of:

* Induction Period (dosing at Weeks 0, 2, and 4)

* Maintenance Dosing (dosing every 4 weeks up to Week 260)

* End of Treatment Visit that occurred at Week 262/Withdrawal Visit and a Safety Follow-up Visit (SFU; 12 weeks after final dose)

Study Timeline

• Study First Submitted: 2007-10-31
• Study First Submitted QC: 2007-10-31
• Study First Posted: 2007-11-01
• Study Start: 2008-05
• Primary Completion: 2014-12
• Study Completion: 2014-12
• Results First Submitted: 2015-12-14
• Results First Submitted QC: 2015-12-14
• Status Verified: 2016-01
• Results First Posted: 2016-01-21
• Last Update Submitted: 2018-07-10
• Last Update Posted: 2018-08-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 403

Inclusion Criteria

• Subject participated in study C87085 [NCT00552058] in which the subject completed the study at Week 6
• Subject is capable of providing informed consent, which must be obtained prior to any study related procedures
• Have a chest X-ray taken at Visit 1 that is read by a qualified radiologist or pulmonary physician, with no evidence of current active Tuberculosis (TB) or old inactive TB
• Subject has taken a TB survey and is committed to comply with TB prophylaxis if applicable

Exclusion Criteria

• Subject is experiencing an ongoing serious adverse event assessed as being related to study medication or is experiencing a serious adverse event that is still not assessable
• Subject has an intercurrent illness that requires termination of treatment, such as a serious infection (e.g. TB, pneumonia, sepsis, pyelonephritis, fistula abscess)
• Subject is non-compliant with TB prophylactic treatment (if applicable)
• Subject has had a chest X-ray at Visit 1 that shows an abnormality suggestive of a malignancy or active infection, including TB
• Female who is pregnant or breast feeding
• Female of child bearing age or post puberty males not practicing effective birth control
• Subject is expecting to receive any live virus or bacterial vaccination within 3 months of first Study Medication administration, during the trial or 3 months after last dose of study drug

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Certolizumab Pegol	Cimzia	Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.

Primary Outcome Measures

Name	Time	Method
Percentage of Subjects With at Least One Serious Adverse Event (SAE) During the Duration of the Study C87088 (up to 272 Weeks)	From study start to the end of the Safety Follow-up Period (up to 272 weeks)	An SAE is defined as any untoward medical occurrence that occurs at any dose which results in death, is life threatening, requires hospitalization, results in persistent/significant disability/incapacity, is an infection that requires parenteral antibiotics, is a congenital anomaly/birth defect, or is an important medical event.
Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)	From study start to the end of the Safety Follow-up Period (up to 272 weeks)	An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Secondary Outcome Measures

Name	Time	Method
Plasma Concentration of Certolizumab Pegol After 1 Year (Week 52)	Week 52	Plasma samples for determination of Certolizumab Pegol were taken prior to Certolizumab Pegol administration.
Percentage of Subjects With Positive Anti-CZP Anti-body Status at Any Time From Week 0 of the Feeder Study C87085 to the Study Completion Visit in C87088	From Week 0 of study C87085 [NCT00552058] to Study Completion Visit (Week 262) of C87088 (up to 268 weeks)	Subjects are counted as antibody positive to Certolizumab Pegol if they have at least one positive result from Week 0 in the previous study C87085 \[NCT00552058\] to the Last Visit in this study. A positive result is defined as Anti-CZP antibody levels \> 2.4 units/mL.
Percentage of Subjects Achieving Harvey Bradshaw Index (HBI) Remission (HBI ≤ 4) at Study Completion Visit (Week 262)	Week 262	HBI remission is defined as total HBI score of 4 points or less. HBI score consists of clinical parameters of general well-being (0 to 4), abdominal pain (0 to 3), number of liquid stools per day, abdominal mass (0 to 3), and complications (8 items, score 1 per item) lower scores indicating better well being. The first three parameters are scored for the previous day.
Percentage of Subjects Achieving Inflamatory Bowel Disease Questionnaire (IBDQ) Remission (IBDQ ≥ 170) at Study Completion Visit (Week 262)	Week 262	IBDQ remission is defined as having a total IBDQ score of 170 points or greater. IBDQ score consists of 32 questions eaching having a score of 1 to 7. Overall scores range from 32 to 224.

Trial Locations

Locations (100)

284; 🇺🇸 Lakewood, Colorado, United States

285; 🇺🇸 Littleton, Colorado, United States

278; 🇺🇸 New Port Richey, Florida, United States

300; 🇺🇸 Winter Park, Florida, United States

276; 🇺🇸 Chicago, Illinois, United States

279; 🇺🇸 Louisville, Kentucky, United States

275; 🇺🇸 Metairie, Louisiana, United States

307; 🇺🇸 Monroe, Louisiana, United States

281; 🇺🇸 Annapolis, Maryland, United States

295; 🇺🇸 Towson, Maryland, United States

Scroll for more (90 remaining)